MNK.N
Latest Trade
4.28USDChange
0.27(+6.73%)Volume
1,529,827Today's Range
-
4.4152 Week Range
-
25.54As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 4.01 |
|---|---|
Open | 3.90 |
Volume | 1,529,827 |
3M AVG Volume | 161.56 |
Today's High | 4.41 |
Today's Low | 3.77 |
52 Week High | 25.54 |
52 Week Low | 1.43 |
Shares Out (MIL) | 84.21 |
Market Cap (MIL) | 337.67 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Mallinckrodt Reports Q4 Adjusted Earnings Per Share $2.40
Morgan Stanley Reports Passive Stake Of 5.1% In Mallinckrodt
Mallinckrodt Enters Creditor Talks Ahead Of Potential Generics Bankruptcy - WSJ
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Executive Leadership
Angus Charles Russell
Independent Non-Executive Chairman of the Board
Mark C. Trudeau
President, Chief Executive Officer, Director
Bryan M. Reasons
Chief Financial Officer
Ian J. Watkins
Chief Human Resource Officer
Steven Romano
Executive Vice President, Chief Scientific Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 0.11 |
Price To Book (MRQ) | 0.17 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 276.95 |
LT Debt To Equity (MRQ) | 244.30 |
Return on Investment (TTM) | -10.69 |
Return on Equity (TTM) | -9.49 |
Mallinckrodt Plc on Tuesday said it had agreed to a $1.6 billion settlement proposal in which its generic drug business would file for bankruptcy in order to resolve thousands of lawsuits alleging it helped fuel the U.S. opioid epidemic.
* Q4 REVENUE VIEW $773.9 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
Drugmaker Mallinckrodt Plc said on Tuesday its specialty generic unit will file for bankruptcy protection as it agreed to settle opioid-related cases globally by paying $1.6 billion over eight years.
Mallinckrodt Plc <MNK.N> is finalizing a settlement proposal of at least $1.6 billion (1.2 billion pounds) that would place its U.S. generic drug business into bankruptcy to address the debt maturities and liabilities arising out of the opioid crisis, the Wall Street Journal...
* MORGAN STANLEY REPORTS A PASSIVE STAKE OF 5.1% IN MALLINCKRODT PLC AS OF FEB 18 - SEC FILING Source: (https://bit.ly/381adDz) Further company coverage:
Drugmaker Mallinckrodt Plc is considering a Chapter 11 filing covering its U.S. generics business, the Wall Street Journal reported on Monday citing people familiar with the matter. (https://on.wsj.com/3c3rwqH)
* MALLINCKRODT ENTERS CREDITOR TALKS AHEAD OF POTENTIAL GENERICS BANKRUPTCY - WSJ
Mallinckrodt Plc said on Tuesday it has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker's lawsuit against the U.S. Department of Health and Human Services (HHS).
Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person...
Mallinckrodt Plc <MNK.N> shares surged more than 50% on Tuesday after it agreed to sell its contract manufacturing unit to reduce debt and its chief executive officer raised hopes that the company could reach a global settlement to resolve all opioid litigation.
Drugmaker Mallinckrodt Plc said on Tuesday it would sell its unit BioVectra Inc to private equity firm H.I.G. Capital for up to $250 million.
Mallinckrodt plc said on Friday it had agreed to pay $24 million in cash to two counties in Ohio, to settle lawsuits related to an ongoing multidistrict opioid litigation in the United States.
Drugmaker Mallinckrodt plc said on Friday it will pay $24 million in cash to two counties in Ohio, to settle lawsuits in connection with an ongoing multidistrict opioid litigation in the United States.
Mallinckrodt Plc on Thursday downplayed a media report that the company had hired restructuring firms and may choose to seek bankruptcy protection.
Mallinckrodt Plc <MNK.N> has hired restructuring firms and may choose to seek bankruptcy protection, Bloomberg reported on Wednesday, sending the drugmaker's shares down 40% in after-hours trading.
Shares of Mallinckrodt Plc <MNK.N> fell 12% on Tuesday after a U.S. Court of Appeals upheld a federal district court's decision to reject the drugmaker's patent infringement lawsuit against Praxair Inc's nitric oxide drug product delivery system.
Mallinckrodt Plc <MNK.N> suspended plans to spin off its specialty generics unit, citing opioid litigation uncertainties, and warned Acthar gel revenue was unlikely to exceed $1 billion this year, sending its shares down about 15% on Tuesday.
Mallinckrodt Plc said on Tuesday it has suspended plans to spin off its specialty generics business, citing uncertainties tied to the opioid litigation and current market conditions.
Mallinckrodt Plc on Wednesday said it had tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.
Mallinckrodt Plc said on Wednesday it reached an agreement with the U.S. Department of Justice to resolve a government investigation into its subsidiary Questcor and expects to pay $15.4 million.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.